

Mounjaro Injection
Mounjaro is a weekly weight loss injection that can help you lose up to 22.5% of your body weight. It's currently considered the most effective weight loss medication on the market.
Get more from Mounjaro with Voy
With Voy, patients lose 53% more weight than with medication alone — thanks to personalised coaching, expert support, and side effects support line.

“Only patients who are currently on the medication or have recently been on it can start on a higher dose"
UK Licensed medication
Free next-day delivery
Cancel anytime subscription
Ongoing medical support
UK Licensed medication
Free next-day delivery
Cancel anytime subscription
Ongoing medical support

What is Mounjaro?
Mounjaro, also known as Tirzepatide, is a clinically-proven prescription medication now available in the UK.
Unlike traditional diet pills, Mounjaro works with your body's natural biology to boost your weight loss success. Specifically, it mimics two important gut hormones—GLP-1 and GIP—which play a key role in regulating appetite and metabolism.


Is Mounjaro safe?
Mounjaro (tirzepatide) has demonstrated a strong safety profile through extensive clinical trials and regulatory review. The medication has received approval from major health authorities, including the UK's MHRA, for weight management.
The most common side effects are mild to moderate stomach issues like nausea, loose stools or constipation. These happen mainly when increasing your dose, but should disappear on their own. Read more on this here.
If you’re currently using Mounjaro (or have recently used it) you can buy the Mounjaro step-up or maintenance dose through Voy.
Treatment starts with a low initial dose, which can be gradually increased every four weeks based on your progress.

Led by the country’s leading obesity experts

Dr. Earim Chaudry is a highly accomplished digital health doctor with extensive experience in the field of online and telemedicine-based healthcare. Over the years, he has played a pivotal role in shaping the landscape of digital healthcare in the UK.
Chief Medical Officer

Anna is a health behaviour change expert and nutritionist with 15 years of experience in coaching. She is the driving force behind the integration of behaviour change psychology into our programme.
Head of Behaviour Change

At the nutritional helm is Molly Morgan, whose career spans various industries including the NHS, pharmaceutical trials and digital health technology start-ups.
Lead Dietitian
In partnership with leading educational and research institutions
How to order Mounjaro
- 1
Complete our questionnaire
Take our online assessment to find out if Mounjaro is right for you.
- 2
Get started
Once you’ve completed our safety checks, start your journey.
- 3
Receive your treatment
We’ll deliver your Mounjaro discreetly to your door.
Participants on the Voy programme lost 5 times more weight than with diet and exercise alone.

Everybody is different and so is every treatment at Voy
Mounjaro FAQ
Dr Earim Chaudry (MBBS), Chief Medical Officer

Medically reviewed on June 24th, 2025.
Mounjaro reviews
"Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study", vol 27 (2025), 31.03.2025, https://www.jmir.org/2025/1/e69466
Aronne, Louis J., et al. “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA, vol. 331, no. 1, 11 Dec. 2023, jamanetwork.com/journals/jama/fullarticle/2812936, https://doi.org/10.1001/jama.2023.24945.
“FDA Approves New Medication for Chronic Weight Management.” FDA, 8 Nov. 2023, www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management.
“How Mounjaro® Works | Mounjaro® (Tirzepatide).” Mounjaro.lilly.com, mounjaro.lilly.com/hcp/how-mounjaro-works.
Lin, Fei, et al. “Weight Loss Efficiency and Safety of Tirzepatide: A Systematic Review.” PLOS One, vol. 18, no. 5, 4 May 2023, doi:10.1371/journal.pone.0285197.
“Tirzepatide For Managing Overweight And Obesity [ID6179].” National Institute For Health And Care Excellence. https://www.nice.org.uk/guidance/indevelopment/gid-ta11156. Accessed 13 Nov. 2024.
Your first step towards weight loss starts here
Today can be life changing
Take the first step towards weight loss that lasts.